Liao Y, Badmann S, Kraus F, Topalov NE, Mayr D, Kolben T, Hester A, Beyer S, Mahner S, Jeschke U, Trillsch F, Czogalla B, Burges A (2023) <br />PLA2G7/PAF-AH as Potential Negative Regulator of the Wnt Signaling Pathway Mediates Protective Effects in BRCA1 Mutant Breast Cancer<br /><i>Int J Mol Sci</i> <b>24</b>: <br /><br />ZulianiZuliani G, Marsillach J, Trentini A, Rosta V, Cervellati C (2023) <br />Lipoprotein-Associated Phospholipase A2 Activity as Potential Biomarker of Vascular Dementia<br /><i>Antioxidants (Basel)</i> <b>12</b>: 597<br /><br />Ma S, Ding L, Cai M, Chen L, Yan B, Yang J (2022) <br />Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease<br /><i>Dis Markers</i> <b>2022</b>: 9775699<br /><br />Tian Y, Fan Y, Chen L, Sun M (2022) <br />Changes and significance of serum monocyte chemoattractant protein-1 and Lp-PLA2 in patients with hypertension and coronary heart disease<br /><i>J Pak Med Assoc</i> <b>72</b>: 1114<br /><br />Li X, Chandra D, Letarte S, Adam GC, Welch J, Yang RS, Rivera S, Bodea S, Dow A, Chi A, Strulson CA, Richardson DD (2021) <br />Profiling Active Enzymes for Polysorbate Degradation in Biotherapeutics by Activity-Based Protein Profiling<br /><i>Analytical Chemistry</i> <b>93</b>: 8161<br /><br />Gu X, Lin W, Xu Y, Che D, Tan Y, Lu Z, Pi L, Fu L, Zhou H, Jiang Z (2020) <br />The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population<br /><i>Front Pediatr</i> <b>8</b>: 338<br /><br />Huang F, Wang K, Shen J (2020) <br />Lipoprotein-associated phospholipase A2: The story continues<br /><i>Med Res Rev</i> <b>40</b>: 79<br /><br />Khan MI, Hariprasad G (2020) <br />Structural Modeling of Wild and Mutant Forms of Human Plasma Platelet Activating Factor-Acetyl Hydrolase Enzyme<br /><i>J Inflamm Res</i> <b>13</b>: 1125<br /><br />Santoso A, Heriansyah T, Rohman MS (2020) <br />Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?<br /><i>Curr Cardiol Rev</i> <b>16</b>: 3<br /><br />De Mauri A, Vidali M, Chiarinotti D, Bellomo G, Rolla R (2019) <br />Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients<br /><i>J Nephrol</i> <b>32</b>: 283<br /><br />Hu G, Liu D, Tong H, Huang W, Hu Y, Huang Y (2019) <br />Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis<br /><i>Biomed Res Int</i> <b>2019</b>: 8642784<br /><br />Zhang MM, Zhang CG, Yang CJ, Zhao P, Li YL (2019) <br />The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction<br /><i>Eur Rev Med Pharmacol Sci</i> <b>23</b>: 3960<br /><br />Chi Y, Shi C, Zhang X, Xi Y (2018) <br />Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population<br /><i>J Thromb Thrombolysis</i> <b>46</b>: 125<br /><br />Yang L, Wang H, Zhang Y, Han T, Wang W (2018) <br />The Prognostic Value of Lipoprotein-Associated Phospholipase A(2) in the Long-Term Care of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention<br /><i>Clin Appl Thromb Hemost</i> <b>24</b>: 822<br /><br />Gregson JM, Freitag DF, Surendran P, Stitziel NO, Chowdhury R, Burgess S, Kaptoge S, Gao P, Staley JR, Willeit P, Nielsen SF, Caslake M, Trompet S, Polfus LM, Kuulasmaa K, Kontto J, Perola M, Blankenberg S, Veronesi G, Gianfagna F, Mannisto S, Kimura A, Lin H, Reilly DF, Gorski M, Mijatovic V, Munroe PB, Ehret GB, Thompson A, Uria-Nickelsen M, Malarstig A, Dehghan A, Vogt TF, Sasaoka T, Takeuchi F, Kato N, Yamada Y, Kee F, Muller-Nurasyid M, Ferrieres J, Arveiler D, Amouyel P, Salomaa V, Boerwinkle E, Thompson SG, Ford I, Wouter Jukema J, Sattar N, Packard CJ, Shafi Majumder AA, Alam DS, Deloukas P, Schunkert H, Samani NJ, Kathiresan S, Nordestgaard BG, Saleheen D, Howson JM, Di Angelantonio E, Butterworth AS, Danesh J (2017) <br />Genetic invalidation of Lp-PLA(2) as a therapeutic target: Large-scale study of five functional Lp-PLA(2)-lowering alleles<br /><i>Eur J Prev Cardiol</i> <b>24</b>: 492<br /><br />Kim M, Yoo HJ, Jang HY, Lee SH, Lee JH (2017) <br />Effects of overweight and the PLA2G7 V279F polymorphism on the association of age with systolic blood pressure<br /><i>PLoS ONE</i> <b>12</b>: e0173611<br /><br />Liu Q, Huang F, Yuan X, Wang K, Zou Y, Shen J, Xu Y (2017) <br />Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2<br /><i>Journal of Medicinal Chemistry</i> <b>60</b>: 10231<br /><br />Measom ND, Down KD, Hirst DJ, Jamieson C, Manas ES, Patel VK, Somers DO (2017) <br />Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor<br /><i>ACS Med Chem Lett</i> <b>8</b>: 43<br /><br />Ni J, Gu H, Hu W, Zhou F, Zhu X, Wang K (2017) <br />Association of Lp-PLA2 G994T gene polymorphism with risk of ischemic stroke in Chinese population<br /><i>J Biochem Mol Toxicol</i> <b>31</b>: <br /><br />Santoso A, Maulana R, Alzahra F, Maghfirah I, Putrinarita AD, Heriansyah T (2017) <br />Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis<br /><i>Am J Cardiovasc Dis</i> <b>7</b>: 122<br /><br />Yang L, Liu Y, Wang S, Liu T, Cong H (2017) <br />Association between Lp-PLA2 and coronary heart disease in Chinese patients<br /><i>J Internal Medicine Res</i> <b>45</b>: 159<br /><br />Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, Macphee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D (2017) <br />Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib<br /><i>PLoS ONE</i> <b>12</b>: e0182115<br /><br />Benderly M, Sapir B, Kalter-Leibovici O, Zimlichman R (2016) <br />Lipoprotein-associated phospholipase A, and subsequent cardiovascular events and mortality among patients with coronary heart disease<br /><i>Biomarkers</i> <br /><br />Cahyaningtias M, Rohman MS, Widodo, Wahjono Adi A, Yuda R, Indrayana Y, Putri JF, Rusdianto, Lukitasari M, Hendrawan D (2016) <br />Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction<br /><i>Genes Dis</i> <b>3</b>: 289<br /><br />Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J (2016) <br />Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema<br /><i>Journal of Medicinal Chemistry</i> <b>59</b>: 2674<br /><br />Haghdoost F, Gharzi M, Faez F, Hosseinzadeh E, Tajaddini M, Ra Ei L, Asgari F, Banihashemi M, Masjedi SS, Zandifar A, Haghjooy-Javanmard S (2016) <br />Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population<br /><i>Iran Journal of Neurology</i> <b>15</b>: 80<br /><br />Liu Q, Chen X, Chen W, Yuan X, Su H, Shen J, Xu Y (2016) <br />Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors<br /><i>Journal of Medicinal Chemistry</i> <b>59</b>: 5115<br /><br />Millwood IY, Bennett DA, Walters RG, Clarke R, Waterworth D, Johnson T, Chen Y, Yang L, Guo Y, Bian Z, Hacker A, Yeo A, Parish S, Hill MR, Chissoe S, Peto R, Cardon L, Collins R, Li L, Chen Z (2016) <br />A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults<br /><i>Int J Epidemiol</i> <b>45</b>: 1588<br /><br />Woolford AJ, Day PJ, Beneton V, Berdini V, Coyle JE, Dudit Y, Grondin P, Huet P, Lee LY, Manas ES, McMenamin RL, Murray CW, Page LW, Patel VK, Potvain F, Rich SJ, Sang Y, Somers DO, Trottet L, Wan Z, Zhang X (2016) <br />Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)<br /><i>Journal of Medicinal Chemistry</i> <b>59</b>: 10738<br /><br />Woolford AJ, Pero JE, Aravapalli S, Berdini V, Coyle JE, Day PJ, Dodson AM, Grondin P, Holding FP, Lee LY, Li P, Manas ES, Marino J, Jr., Martin AC, McCleland BW, McMenamin RL, Murray CW, Neipp CE, Page LW, Patel VK, Potvain F, Rich S, Rivero RA, Smith K, Somers DO, Trottet L, Velagaleti R, Williams G, Xie R (2016) <br />Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening<br /><i>Journal of Medicinal Chemistry</i> <b>59</b>: 5356<br /><br />Chen X, Xu W, Wang K, Mo M, Zhang W, Du L, Yuan X, Xu Y, Wang Y, Shen J (2015) <br />Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors<br /><i>Journal of Medicinal Chemistry</i> <b>58</b>: 8529<br /><br />Hong M, Zhang M, Lu X (2015) <br />Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population<br /><i>Mamm Genome</i> <b>26</b>: 191<br /><br />Karasawa K (2015) <br />Naturally Occurring Missense Mutation in Plasma PAF-AH Among the Japanese Population<br /><i>Enzymes</i> <b>38</b>: 117<br /><br />Kirby SD, Norris J, Sweeney R, Bahnson BJ, Cerasoli DM (2015) <br />A rationally designed mutant of plasma platelet-activating factor acetylhydrolase hydrolyzes the organophosphorus nerve agent soman<br /><i>Biochimica & Biophysica Acta</i> <b>1854</b>: 1809<br /><br />Maiolino G, Lenzini L, Pedon L, Cesari M, Seccia TM, Frigo AC, Rossitto G, Caroccia B, Rossi GP (2015) <br />Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease<br /><i>J Cardiovasc Med (Hagerstown)</i> <b>16</b>: 29<br /><br />Xu RX, Zhang Y, Li XL, Li S, Guo YL, Dong Q, Liu G, Li JJ (2015) <br />Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease<br /><i>Clinica Chimica Acta</i> <b>446</b>: 195<br /><br />Zheng GH, Xiong SQ, Chen HY, Mei LJ, Wang T (2014) <br />Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population<br /><i>Mol Biol Rep</i> <b>41</b>: 7141<br /><br />White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A (2013) <br />Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study<br /><i>J Am Heart Assoc</i> <b>2</b>: e000360<br /><br />Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, Lu C, Smith NL, Uitterlinden AG, Roberts R, Khuseyinova N, Schnabel RB, Rice KM, Rivadeneira F, Hoogeveen RC, Fontes JD, Meisinger C, Keaney JF, Jr., Lemaitre R, Aulchenko YS, Vasan RS, Ellis S, Hazen SL, van Duijn CM, Nelson JJ, Marz W, Schunkert H, McPherson RM, Stirnadel-Farrant HA, Psaty BM, Gieger C, Siscovick D, Hofman A, Illig T, Cushman M, Yamamoto JF, Rotter JI, Larson MG, Stewart AF, Boerwinkle E, Witteman JC, Tracy RP, Koenig W, Benjamin EJ, Ballantyne CM (2012) <br />Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies<br /><i>Eur Heart J</i> <b>33</b>: 238<br /><br />Maiolino G, Pedon L, Cesari M, Frigo AC, Wolfert RL, Barisa M, Pagliani L, Rossitto G, Seccia TM, Zanchetta M, Rossi GP (2012) <br />Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients<br /><i>PLoS ONE</i> <b>7</b>: e48171<br /><br />Song K, Nelson MR, Aponte J, Manas ES, Bacanu SA, Yuan X, Kong X, Cardon L, Mooser VE, Whittaker JC, Waterworth DM (2012) <br />Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations<br /><i>Pharmacogenomics J</i> <b>12</b>: 425<br /><br />Colley KJ, Wolfert RL, Cobble ME (2011) <br />Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk<br /><i>EPMA J</i> <b>2</b>: 27<br /><br />Jang Y, Waterworth D, Lee JE, Song K, Kim S, Kim HS, Park KW, Cho HJ, Oh IY, Park JE, Lee BS, Ku HJ, Shin DJ, Lee JH, Jee SH, Han BG, Jang HY, Cho EY, Vallance P, Whittaker J, Cardon L, Mooser V (2011) <br />Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males<br /><i>PLoS ONE</i> <b>6</b>: e18208<br /><br />Li L, Qi L, Lv N, Gao Q, Cheng Y, Wei Y, Ye J, Yan X, Dang A (2011) <br />Association between lipoprotein-associated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population<br /><i>Ann Hum Genet</i> <b>75</b>: 605<br /><br />Zheng GH, Chen HY, Xiong SQ, Chu JF (2011) <br />Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis<br /><i>Mol Biol Rep</i> <b>38</b>: 4089<br /><br />Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL, Sofat R, Nicolaides AN, Corsetti JP, Fowkes FG, Tzoulaki I, Kumari M, Brunner EJ, Kivimaki M, Marmot MG, Hoffmann MM, Winkler K, Marz W, Ye S, Stirnadel HA, Boekholdt SM, Khaw KT, Humphries SE, Sandhu MS, Hingorani AD, Talmud PJ (2010) <br />PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry<br /><i>Circulation</i> <b>121</b>: 2284<br /><br />Fan P, Liu Hw, Wang XS, Zhang F, Song Q, Li Q, Wu HM, Bai H (2010) <br />Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome<br /><i>Hum Reprod</i> <b>25</b>: 1288<br /><br />Toth PP, McCullough PA, Wegner MS, Colley KJ (2010) <br />Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker<br /><i>Expert Rev Cardiovasc Ther</i> <b>8</b>: 425<br /><br />Wang Q, Hao Y, Mo X, Wang L, Lu X, Huang J, Cao J, Li H, Gu D (2010) <br />PLA2G7 gene polymorphisms and coronary heart disease risk: a meta-analysis<br /><i>Thromb Res</i> <b>126</b>: 498<br /><br />Hoffmann MM, Winkler K, Renner W, Winkelmann BR, Seelhorst U, Wellnitz B, Boehm BO, Marz W (2009) <br />Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study)<br /><i>J Thromb Haemost</i> <b>7</b>: 41<br /><br />Hou L, Chen S, Yu H, Lu X, Chen J, Wang L, Huang J, Fan Z, Gu D (2009) <br />Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study<br /><i>Hum Genet</i> <b>125</b>: 11<br /><br />Li S, Stuart L, Zhang Y, Meduri GU, Umberger R, Yates CR (2009) <br />Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype<br /><i>J Clin Pharm Ther</i> <b>34</b>: 447<br /><br />Samanta U, Kirby SD, Srinivasan P, Cerasoli DM, Bahnson BJ (2009) <br />Crystal structures of human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents exhibit non-aged complexes<br /><i>Biochemical Pharmacology</i> <b>78</b>: 420<br /><br />Wang T, Karino K, Yamasaki M, Zhang Y, Masuda J, Yamaguchi S, Shiwaku K, Nabika T (2009) <br />Effects of G994T in the Lp-PLA2 gene on the plasma oxidized LDL level and carotid intima-media thickness in Japanese: the Shimane study<br /><i>Am J Hypertens</i> <b>22</b>: 742<br /><br />Gardner AA, Reichert EC, Topham MK, Stafforini DM (2008) <br />Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein<br /><i>Journal of Biological Chemistry</i> <b>283</b>: 17099<br /><br />Samanta U, Bahnson BJ (2008) <br />Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis<br /><i>Journal of Biological Chemistry</i> <b>283</b>: 31617<br /><br />Sutton BS, Crosslin DR, Shah SH, Nelson SC, Bassil A, Hale AB, Haynes C, Goldschmidt-Clermont PJ, Vance JM, Seo D, Kraus WE, Gregory SG, Hauser ER (2008) <br />Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets<br /><i>Hum Mol Genet</i> <b>17</b>: 1318<br /><br />Wilensky RL, Shi Y, Mohler ER, 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH (2008) <br />Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development<br /><i>Nat Med</i> <b>14</b>: 1059<br /><br />Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Sacco R, Elkind M, Talmud P, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Wassertheil-Smoller S, Ridker P, Danesh J, Gu D, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Walker M, Watson S, Wood A (2007) <br />Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases<br /><i>Eur J Cardiovasc Prev Rehabil</i> <b>14</b>: 3<br /><br />Wootton PT, Flavell DM, Montgomery HE, World M, Humphries SE, Talmud PJ (2007) <br />Lipoprotein-associated phospholipase A2 A379V variant is associated with body composition changes in response to exercise training<br /><i>Nutr Metab Cardiovasc Dis</i> <b>17</b>: 24<br /><br />Zhang SY, Shibata H, Karino K, Wang BY, Kobayashi S, Masuda J, Nabika T (2007) <br />Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population<br /><i>Hypertens Res</i> <b>30</b>: 403<br /><br />Jang Y, Kim OY, Koh SJ, Chae JS, Ko YG, Kim JY, Cho H, Jeong TS, Lee WS, Ordovas JM, Lee JH (2006) <br />The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men<br /><i>J Clinical Endocrinology Metab</i> <b>91</b>: 3521<br /><br />Liu PY, Li YH, Wu HL, Chao TH, Tsai LM, Lin LJ, Shi GY, Chen JH (2006) <br />Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction<br /><i>J Thromb Haemost</i> <b>4</b>: 1023<br /><br />Sekuri C, Cam FS, Tengiz I, Ercan E, Bayturan O, Berdeli A (2006) <br />Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients<br /><i>Anadolu Kardiyol Derg</i> <b>6</b>: 132<br /><br />Mashiba J, Koike G, Kamiunten H, Ikeda M, Sunagawa K (2005) <br />Vasospastic angina and microvascular angina are differentially influenced by PON1 A632G polymorphism in the Japanese<br /><i>Circ J</i> <b>69</b>: 1466<br /><br />Ishihara M, Iwasaki T, Nagano M, Ishii J, Takano M, Kujiraoka T, Tsuji M, Hattori H, Emi M (2004) <br />Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients<br /><i>J Hum Genet</i> <b>49</b>: 302<br /><br />Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, Rupprecht HJ, Cambien F, Blankenberg S, Tiret L (2004) <br />Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease<br /><i>Hum Mol Genet</i> <b>13</b>: 1341<br /><br />Abuzeid AM, Hawe E, Humphries SE, Talmud PJ (2003) <br />Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe<br /><i>Atherosclerosis</i> <b>168</b>: 283<br /><br />Yamamoto I, Fujitsu J, Nohnen S, Igarashi T, Motomura T, Inaba M, Tsubakimori S, Azuma J (2003) <br />Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients<br /><i>Diabetes Res Clin Pract</i> <b>59</b>: 219<br /><br />Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C (2001) <br />Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan<br /><i>Thromb Res</i> <b>101</b>: 231<br /><br />Petrovic N, Grove C, Langton PE, Misso NL, Thompson PJ (2001) <br />A simple assay for a human serum phospholipase A2 that is associated with high-density lipoproteins<br /><i>J Lipid Res</i> <b>42</b>: 1706<br /><br />Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA (2000) <br />The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma<br /><i>American Journal of Human Genetics</i> <b>66</b>: 1522<br /><br />Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD (2000) <br />Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group<br /><i>N Engl J Med</i> <b>343</b>: 1148<br /><br />Xu H, Iijima K, Shirakawa T, Shiozawa S, Miwa M, Yamaoka K, Kawamura N, Nakamura H, Yoshikawa N (2000) <br />Platelet-activating factor acetylhydrolase gene mutation in Japanese children with Escherichia coli O157-associated hemolytic uremic syndrome<br /><i>Am J Kidney Dis</i> <b>36</b>: 42<br /><br />Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M (2000) <br />Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population<br /><i>Atherosclerosis</i> <b>150</b>: 209<br /><br />Stafforini DM, Numao T, Tsodikov A, Vaitkus D, Fukuda T, Watanabe N, Fueki N, McIntyre TM, Zimmerman GA, Makino S, Prescott SM (1999) <br />Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma<br /><i>J Clinical Investigation</i> <b>103</b>: 989<br /><br />Tanaka R, Iijima K, Xu H, Inoue Y, Murakami R, Shirakawa T, Nishiyama K, Miwa M, Shiozawa S, Nakamura H, Yoshikawa N (1999) <br />Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy<br /><i>Am J Kidney Dis</i> <b>34</b>: 289<br /><br />Wjst M, Fischer G, Immervoll T, Jung M, Saar K, Rueschendorf F, Reis A, Ulbrecht M, Gomolka M, Weiss EH, Jaeger L, Nickel R, Richter K, Kjellman NI, Griese M, von Berg A, Gappa M, Riedel F, Boehle M, van Koningsbruggen S, Schoberth P, Szczepanski R, Dorsch W, Silbermann M, Loesgen S, Scholz M, Bickeboller H, Wichmann HE (1999) <br />A genome-wide search for linkage to asthma. German Asthma Genetics Group<br /><i>Genomics</i> <b>58</b>: 1<br /><br />Ober C, Cox NJ, Abney M, Di Rienzo A, Lander ES, Changyaleket B, Gidley H, Kurtz B, Lee J, Nance M, Pettersson A, Prescott J, Richardson A, Schlenker E, Summerhill E, Willadsen S, Parry R (1998) <br />Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the Genetics of Asthma<br /><i>Hum Mol Genet</i> <b>7</b>: 1393<br /><br />Xu H, Iijima K, Shiozawa S, Tanaka SS, Inoue Y, Shirakawa T, Nishiyama K, Miwa M, Nakamura H, Yoshikawa N (1998) <br />Platelet-activating factor acetylhydrolase gene mutation in Japanese nephrotic children<br /><i>Kidney Int</i> <b>54</b>: 1867<br /><br />Yamada Y, Ichihara S, Fujimura T, Yokota M (1998) <br />Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men<br /><i>Metabolism</i> <b>47</b>: 177<br /><br />Yoshida H, Imaizumi T, Fujimoto K, Itaya H, Hiramoto M, Yoshimizu N, Fukushi K, Satoh K (1998) <br />A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension<br /><i>Thromb Haemost</i> <b>80</b>: 372<br /><br />Bell R, Collier DA, Rice SQ, Roberts GW, Macphee CH, Kerwin RW, Price J, Gloger IS (1997) <br />Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia<br /><i>Biochemical & Biophysical Research Communications</i> <b>241</b>: 630<br /><br />Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K (1997) <br />A mutation in plasma platelet-activating factor acetylhydrolase (Val279--&gt;Phe) is a genetic risk factor for stroke<br /><i>Stroke</i> <b>28</b>: 2417<br /><br />Yamada Y, Yokota M (1997) <br />Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation<br /><i>Biochemical & Biophysical Research Communications</i> <b>236</b>: 772<br /><br />Nadel JA (1996) <br />Genetics reveals importance of platelet activating factor in asthma and possibly other inflammatory states<br /><i>J Clinical Investigation</i> <b>97</b>: 2689<br /><br />Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM (1996) <br />Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase<br /><i>J Clinical Investigation</i> <b>97</b>: 2784<br /><br />Svetlov SI, Howard KM, Miwa M, Flickinger BD, Olson MS (1996) <br />Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation<br /><i>Archives of Biochemistry & Biophysics</i> <b>327</b>: 113<br /><br />Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH (1996) <br />Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins<br /><i>Arterioscler Thromb Vasc Biol</i> <b>16</b>: 591<br /><br />Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM (1995) <br />Anti-inflammatory properties of a platelet-activating factor acetylhydrolase<br /><i>Nature</i> <b>374</b>: 549<br /><br />Furukawa M, Narahara H, Yasuda K, Johnston JM (1993) <br />Presence of platelet-activating factor-acetylhydrolase in milk<br /><i>J Lipid Res</i> <b>34</b>: 1603<br /><br />Washburn WN, Dennis (1990) <br />Novel General Approach for the Assay and Inhibition of Hydrolytic Enzymes Utilizing Suicide-Inhibitory Bifunctionally Linked Substrates (SIBLINKS): Exemplified by a Phospholipase A2 Assay<br /><i>Journal of the American Chemical Society</i> <b>112</b>: 2040<br /><br />Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M (1988) <br />Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children<br /><i>J Clinical Investigation</i> <b>82</b>: 1983<br /><br />